AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19200537 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2 (relationship between promiscuous teleology and other variables)
Number of subjects: 0
Study 16845641 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day, titrated to 90 mg/day after 1 week, then to 120 mg/day after another week, maintained for 4 weeks
Number of subjects: 128
Study 16845641 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 128
Study 16845641 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day, 90 mg/day, 120 mg/day
Number of subjects: 128
Study 15455235 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) worn during the 80-min recovery period
Number of subjects: 12
Study 11099373 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg á kg‐1 body mass
Number of subjects: 8
Study 11099373 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg á kg‐1 body mass
Number of subjects: 8
Study 11099373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9300761 — intervention group
Group type: EXPERIMENTAL
Intervention: Multileaf collimator (MLC) on Philips SL‐25 linear accelerator (6 MV photons)
Number of subjects: 20
Study 9300761 — intervention group
Group type: COMPARATOR
Intervention: Tray-mounted cerrobend blocks on Philips SL‐75 linear accelerator (5 MV photons)
Number of subjects: 20
Study 8341134 — intervention group
Group type: EXPERIMENTAL
Intervention: THA (tacrine)
Number of subjects: 10
Study 8341134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 10
Study 3523711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) in high dose (2.1 g daily)
Number of subjects: 390
Study 3523711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) in low dose (1.05 g daily)
Number of subjects: 390
Study 3523711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 31356452 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and water
Number of subjects: 242
Study 31356452 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and 24% sucrose
Number of subjects: 242
Study 31356452 — intervention group
Group type: COMPARATOR
Intervention: 24% sucrose
Number of subjects: 242
Study 29937255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation strategies
Number of subjects: 39
Study 29937255 — intervention group
Group type: COMPARATOR
Intervention: Standardized implementation strategies
Number of subjects: 39
Study 27373387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative aberrometry measurements (Ocular Response Analyzer with Verifeye)
Number of subjects: 130
Study 27373387 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative biometry and toric IOL calculator with inked axis marking
Number of subjects: 130
Study 24953914 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine nebulized therapy
Number of subjects: 100
Study 24953914 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol nebulized aerosol
Number of subjects: 100
Study 21873370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDT) with oesophageal Doppler monitoring (ODM)
Number of subjects: 179
Study 21873370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDT)
Number of subjects: 179
Study 21873370 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen without ODM-guided intraoperative GDT
Number of subjects: 179
Study 20067958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 0
Study 20067958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 0
Study 20067958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18700304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Amikacin FDC (2.5g b.i.d)
Number of subjects: 200
Study 18700304 — intervention group
Group type: COMPARATOR
Intervention: Cefepime alone (2.0g b.i.d)
Number of subjects: 200
Study 15616893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (15 mg per day) in addition to GC (group B)
Number of subjects: 20
Study 15616893 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids alone (group A)
Number of subjects: 20
Study 12777950 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide dismutase
Number of subjects: 24
Study 12777950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment adjustment
Number of subjects: 24
Study 12777950 — intervention group
Group type: COMPARATOR
Intervention: NG‐monomethyl‐l‐arginine
Number of subjects: 24
Study 12777950 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 24
Study 12777950 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 24
Study 10680418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoracaine
Number of subjects: 30
Study 10680418 — intervention group
Group type: COMPARATOR
Intervention: Fluorox
Number of subjects: 30
Study 8723170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg daily (n = 9)
Number of subjects: 17
Study 8723170 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (n = 8)
Number of subjects: 17
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial cell sarcoma
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosarcoma
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant fibrous histiocytoma
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant neurogenic tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors of the trunk
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III tumors
Number of subjects: 75
Study 1314309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV tumors
Number of subjects: 75
Study 3892993 — intervention group
Group type: EXPERIMENTAL
Intervention: ALB (80 g albumin on the day of operation and 20 g for the following 3 days)
Number of subjects: 26
Study 3892993 — intervention group
Group type: COMPARATOR
Intervention: NON-ALB (no extra albumin)
Number of subjects: 26
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: ConTxt only (SMS intervention)
Number of subjects: 298
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls
Number of subjects: 298
Study 31553725 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard print materials)
Number of subjects: 298
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls vs Control group
Number of subjects: 298
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: ConTxt only vs Control group
Number of subjects: 298
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls vs ConTxt only
Number of subjects: 298
Study 31553725 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish speakers vs English speakers in ConTxt plus health-coaching calls
Number of subjects: 298
Study 27743840 — intervention group
Group type: EXPERIMENTAL
Intervention: PAVeD
Number of subjects: 203
Study 27743840 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 26181014 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 97
Study 23950057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 13
Study 23950057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 21715107 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 15 mg bid
Number of subjects: 112
Study 21715107 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 30 mg bid
Number of subjects: 112
Study 21715107 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study 19564368 — intervention group
Group type: COMPARATOR
Intervention: 320 mg gemifloxacin as an oral tablet without probenecid
Number of subjects: 17
Study 19564368 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg gemifloxacin as an oral tablet with 4.5 g probenecid divided in eight oral doses
Number of subjects: 17
Study 16219709 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28 remission criterion (cut off level: 2.6)
Number of subjects: 155
Study 16219709 — intervention group
Group type: COMPARATOR
Intervention: DAS remission criterion (cut off level: 1.6)
Number of subjects: 155
Study 16219709 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Joint Count (TJC) >0
Number of subjects: 155
Study 16219709 — intervention group
Group type: EXPERIMENTAL
Intervention: Swollen Joint Count >0
Number of subjects: 155
Study 16219709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity joint involvement
Number of subjects: 155
Study 15518674 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention by a qualified therapist plus care as usual by a general practitioner (GP)
Number of subjects: 98
Study 15518674 — intervention group
Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 98
Study 11701572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (caseload 10‐15 per case manager) for two years
Number of subjects: 708
Study 11701572 — intervention group
Group type: COMPARATOR
Intervention: Standard case management (30‐35 per case manager)
Number of subjects: 708
Study 9385499 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler inhaler
Number of subjects: 213
Study 9385499 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 213
Study 9385499 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 213
Study 7944875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 43
Study 7944875 — intervention group
Group type: COMPARATOR
Intervention: Control test
Number of subjects: 43
Study 3555569 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg
Number of subjects: 80
Study 3555569 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg
Number of subjects: 80
Study 3555569 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 100 mg
Number of subjects: 80
Study 3555569 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 2317416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 40
Study 2317416 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 40
Study 31635258 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumers
Number of subjects: 802
Study 31635258 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 802
Study 31635258 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 802
Study 29045207 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of tofacitinib administered orally twice daily
Number of subjects: 395
Study 29045207 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of tofacitinib administered orally twice daily
Number of subjects: 395
Study 29045207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with a switch to 5 mg of tofacitinib at 3 months)
Number of subjects: 395
Study 24865592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 616
Study 22990950 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal shoulder injection
Number of subjects: 70
Study 22990950 — intervention group
Group type: COMPARATOR
Intervention: IV PCA
Number of subjects: 70
Study 21899843 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin or pitavastatin treatment
Number of subjects: 307
Study 19391543 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion literature analysis
Number of subjects: 4041
Study 16481597 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine 10 g/day
Number of subjects: 200
Study 16481597 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/day
Number of subjects: 200
Study 16481597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12762352 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine inhalation (1.0 parts per million for 15 min)
Number of subjects: 16
Study 12762352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 16
Study 12762352 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 16
Study 12762352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage (post-exposure measurement)
Number of subjects: 16
Study 11487162 — intervention group
Group type: EXPERIMENTAL
Intervention: Geristore
Number of subjects: 100
Study 11487162 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 100
Study 11487162 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot
Number of subjects: 100
Study 11487162 — intervention group
Group type: COMPARATOR
Intervention: Positive control (open root-end cavities)
Number of subjects: 100
Study 11487162 — intervention group
Group type: COMPARATOR
Intervention: Negative control (sticky wax and nail polish)
Number of subjects: 100
Study 9662320 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a movie through video eyeglasses
Number of subjects: 89
Study 9662320 — intervention group
Group type: COMPARATOR
Intervention: Active play (singing, blowing bubbles)
Number of subjects: 89
Study 9662320 — intervention group
Group type: COMPARATOR
Intervention: Passive play (being read to)
Number of subjects: 89
Study 8151150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir granules (40% w/w aciclovir) at a dose of 20 mg/kg four times daily for five to seven days
Number of subjects: 104
Study 8151150 — intervention group
Group type: COMPARATOR
Intervention: Conventional symptomatic therapy
Number of subjects: 104
Study 3061369 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 36
Study 3061369 — intervention group
Group type: EXPERIMENTAL
Intervention: penicillamine
Number of subjects: 36
Study 3061369 — intervention group
Group type: EXPERIMENTAL
Intervention: azathioprine
Number of subjects: 36
Study 3061369 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 age matched controls)
Number of subjects: 36
Study 31916648 — intervention group
Group type: EXPERIMENTAL
Intervention: quadruple‐therapy with 2 g/day N. sativa
Number of subjects: 51
Study 31916648 — intervention group
Group type: COMPARATOR
Intervention: quadruple‐therapy with 2 g/day placebo
Number of subjects: 51
Study 30173153 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) with Methotrexate (MTX) 20 mg/week
Number of subjects: 0
Study 30173153 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) with Methotrexate (MTX) 7.5 mg/week
Number of subjects: 0
Study 30173153 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese patients)
Number of subjects: 0
Study 26361776 — intervention group
Group type: EXPERIMENTAL
Intervention: ExoSeal® vascular closure device (VCD)
Number of subjects: 48
Study 26361776 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 48
Study 25394429 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 80
Study 25394429 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline alone
Number of subjects: 80
Study 23368897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol combination therapy (100/10 μg b.i.d. or 250/10 μg b.i.d.)
Number of subjects: 210
Study 23368897 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone + formoterol (100 μg + 12 μg b.i.d. or 250 μg + 12 μg b.i.d.)
Number of subjects: 210
Study 23368897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol combination therapy
Number of subjects: 210
Study 23368897 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone + formoterol
Number of subjects: 210
Study 20206776 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 3057
Study 20206776 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 3057
Study 18853878 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement three times during the first postoperative week
Number of subjects: 90
Study 18853878 — intervention group
Group type: COMPARATOR
Intervention: Debridement once on the 7th postoperative day (Control)
Number of subjects: 90
Study 17111990 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematically implemented psychotherapy
Number of subjects: 0
Study 17111990 — intervention group
Group type: EXPERIMENTAL
Intervention: Common aspects of all psychotherapies
Number of subjects: 0
Study 17111990 — intervention group
Group type: EXPERIMENTAL
Intervention: Suitability and competence of the psychotherapist
Number of subjects: 0
Study 12725765 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized voxel-based morphometry (VBM) method
Number of subjects: 0
Study 11323554 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g.d‐1 for 5 days)
Number of subjects: 14
Study 11323554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9195406 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (6-9 MU; six times weekly for 2 weeks followed by thrice weekly for 22 additional weeks)
Number of subjects: 43
Study 8186869 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy (20 Gy in four 5 Gy fractions)
Number of subjects: 293
Study 8186869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (20 Gy) plus local microwave hyperthermia
Number of subjects: 293
Study 8186869 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 293
Study 8186869 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with hyperthermia
Number of subjects: 293
Study 3473193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 40
Study 3473193 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 40
Study 30964381 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast for 4 weeks
Number of subjects: 9
Study 30964381 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 9
Study 27135478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua Cycling (AC)
Number of subjects: 20
Study 27135478 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (P)
Number of subjects: 20
Study 25523718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine (TIV) - 60 μg
Number of subjects: 38
Study 25523718 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose trivalent inactivated influenza vaccine (TIV) - 15 μg
Number of subjects: 38
Study 23659825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-sufentanil combined anesthesia with intraoperative wake-up test
Number of subjects: 30
Study 23659825 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-sufentanil combined anesthesia without intraoperative wake-up test
Number of subjects: 30
Study 21850510 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic operation
Number of subjects: 267
Study 21850510 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator operation
Number of subjects: 267
Study 21850510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-urethral sling procedures (overall intervention)
Number of subjects: 267
Study 19571750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine in nondystrophic myotonias
Number of subjects: 0
Study 19571750 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 17713344 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva from 7 subjects (enamel)
Number of subjects: 14
Study 17713344 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva from 6 subjects (dentine)
Number of subjects: 14
Study 17713344 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva from 1 subject
Number of subjects: 14
Study 17713344 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 14
Study 14982697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 48
Study 14982697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg oral)
Number of subjects: 48
Study 14982697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (vs. denicotinized cigarette smoke)
Number of subjects: 48
Study 14982697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vs. ethanol)
Number of subjects: 48
Study 14982697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vs. mecamylamine)
Number of subjects: 48
Study 11420874 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD = 6 x 2 h/week)
Number of subjects: 10
Study 11420874 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (SHD = 3 x 4 h/week)
Number of subjects: 10
Study 11420874 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 9665186 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensification block
Number of subjects: 0
Study 9665186 — intervention group
Group type: COMPARATOR
Intervention: Late intensification block
Number of subjects: 0
Study 8073910 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine (alpha adrenergic receptor antagonist)
Number of subjects: 36
Study 8073910 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (alpha-1 adrenergic receptor agonist)
Number of subjects: 36
Study 2673620 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (0.07 mg/kg/min)
Number of subjects: 10